Logo image of AFJK

AIMEI HEALTH TECHNOLOGY CO (AFJK) Stock Fundamental Analysis

NASDAQ:AFJK - Nasdaq - KYG013411098 - Common Stock - Currency: USD

11.0299  +0.03 (+0.27%)

Fundamental Rating

1

AFJK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. AFJK has a bad profitability rating. Also its financial health evaluation is rather negative. AFJK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AFJK had positive earnings in the past year.
In the past year AFJK has reported a negative cash flow from operations.
AFJK Yearly Net Income VS EBIT VS OCF VS FCFAFJK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1M -1M 2M

1.2 Ratios

Industry RankSector Rank
ROA 3.46%
ROE 3.53%
ROIC N/A
ROA(3y)1.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AFJK Yearly ROA, ROE, ROICAFJK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 1 -1 2 3

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AFJK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AFJK Yearly Profit, Operating, Gross MarginsAFJK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

AFJK has a worse debt/assets ratio than last year.
AFJK Yearly Shares OutstandingAFJK Yearly Shares OutstandingYearly Shares Outstanding 2022 2024 2M 4M 6M
AFJK Yearly Total Debt VS Total AssetsAFJK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 26.79 indicates that AFJK is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.00 indicates that AFJK is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.79
ROIC/WACCN/A
WACCN/A
AFJK Yearly LT Debt VS Equity VS FCFAFJK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.04 indicates that AFJK may have some problems paying its short term obligations.
AFJK has a Quick Ratio of 0.04. This is a bad value and indicates that AFJK is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
AFJK Yearly Current Assets VS Current LiabilitesAFJK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200K 400K 600K 800K

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1388.42% over the past year.
EPS 1Y (TTM)1388.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 39.39, the valuation of AFJK can be described as expensive.
AFJK's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 28.79.
Industry RankSector Rank
PE 39.39
Fwd PE N/A
AFJK Price Earnings VS Forward Price EarningsAFJK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AFJK Per share dataAFJK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AFJK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIMEI HEALTH TECHNOLOGY CO

NASDAQ:AFJK (4/25/2025, 8:00:00 PM)

11.0299

+0.03 (+0.27%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners103.98%
Inst Owner ChangeN/A
Ins Owners2.48%
Ins Owner Change-5.75%
Market Cap67.50M
AnalystsN/A
Price TargetN/A
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 39.39
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB 0.93
EV/EBITDA N/A
EPS(TTM)0.28
EY2.54%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS11.82
TBVpS11.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 3.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)1.23%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z 26.79
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1388.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3636.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A